The Company

Novapep is an Australian-US biotech company which has developed its PARagon Peptide Platform of structured PAR agonist peptides which mimic the mechanisms of Activated Protein C ('APC') for treatment of diseases and conditions with unmet medical needs.  The Company’s target diseases are inflammatory skin disorders and inflammatory bowel disease ('IBD').  Novapep is also researching G10 in cerebral malaria - which kills over 300,000 African children a year.

Novapep’s co-founders, Professor John Griffin and Professor Laurent Mosnier at the Scripps Research Institute in San Diego, have conducted over 15 years of ground-breaking R&D in APC, ultimately resulting in the invention of the TR47, P3R and G10 agonist peptide mimetics of APC, which are the cornerstone peptides of Novapep’s PARagon Peptide Platform. 

 

Novapep has licensed the TR47 and G10 patents from the Scripps, which provide IP protection to 2039.

 

Professor Chris Jackson at the University of Sydney has published more than 60 papers in APC in inflammatory skin disorders and an initial study of TR47 in atopic dermatitis; and he leads Novapep's G10 dermatitis and burns program.  Prof Silvio Danese, a world expert in IBD, has published papers showing APC is effective in the treatment of IBD; and he leads Novapep's G10 IBD program.

 

The competitive advantages of Novapep’s PARagon Peptide   Platform include:

TM

  • Novapep’s APC mimetic peptides are far cheaper to manufacture, are stable and are ideal therapeutics for dermatitis and burns (topical), inflammatory bowel disease (oral) and cerebral malaria (systemic) delivery.

 

  • Current treatments for these indications have low efficacy, significant side effects and/or are far more expensive to manufacture that the G10 structures and formulations.

  • G10 exerts multiple protective mechanisms of action in target diseases.

  • Successful translation of the G10 structures and formulations will make them first in class drugs for Novapep's target indications.